Golden
Nabriva Therapeutics

Nabriva Therapeutics

A biopharmaceutical company focused on the research and development of antibiotics to treat serious infections

All edits

Edits on 17 Jun 2019
Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 17 Jun 2019 6:32 am
Edits made to:
Article (+6/-6 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland that was founded in 2006 by Rodger Novak. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (ViennaVienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Edits on 15 Jun 2019
Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 15 Jun 2019 8:10 am
Edits made to:
Article (+12/-12 characters)

Article

On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo CapitalVivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund. 

Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 15 Jun 2019 6:40 am
Edits made to:
Article (+6/-6 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland that was founded in 2006 by Rodger Novak. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from SandozSandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 9:34 pm
Edits made to:
Infobox (+1 properties)
Edits on 31 Mar 2019
Dawson Sewell
Dawson Sewell edited on 31 Mar 2019 10:36 am
Edits made to:
Infobox (+9/-1 properties)
Timeline (+3 events) (+796 characters)
Article (+784 characters)
Categories (-1 topics)
Related Topics (+1 topics)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland that was founded in 2006 by Rodger Novak. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

...

Funding

Venture

On October 28, 2009 Nabriva Therapeutics completed a venture capital round with $22 million in funding from Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund. 

Series B

On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund. 

Long term loan

On December 21, 2018 Nabriva Therapeutics came to a long term loan agreement for a loan of $75 million from Hercules Capital; and $25 million was funded at the closing of the long term loan deal. 

Infobox

Categories

Related Topics

Timeline

December 21, 2018

Long term loan agreement with Hercules Capital

On December 21, 2018 Nabriva Therapeutics came to a long term loan agreement for a loan of $75 million from Hercules Capital; and $25 million was funded at the closing of the long term loan deal. 

May 7, 2015

Series B funding round

On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund. 

October 28, 2009

Venture funding round

On October 28, 2009 Nabriva Therapeutics completed a venture capital round with $22 million in funding from Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund. 

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:16 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 10:08 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 8 Jan 2019
Carla Faraguna
Carla Faraguna edited on 8 Jan 2019 11:17 pm
Edits made to:
Categories (+1/-1 topics)
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 8 Jan 2019 11:16 pm
Edits made to:
Article (+19/-19 characters)

Article

  • Hospital-acquired bacterial pneumoniabacterial pneumonia (HABP) & Ventilator-associated bacterial pneumonia (VABP)
Edits on 4 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 4 Jan 2019 2:35 am
Edits made to:
Article (+7/-7 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, IrelandIreland. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Edits on 29 Dec 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Dec 2018 2:06 am
Edits made to:
Article (+7/-7 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and AustriaAustria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Dec 2018 2:04 am
Edits made to:
Article (+9/-9 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland. It also has facilities in the US (King of Prussia, PA & San DiegoSan Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Edits on 28 Dec 2018
Thomas Shaddox
Thomas Shaddox approved a suggestion from Golden's AI on 28 Dec 2018 5:28 am
Edits made to:
Article (+6/-6 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in DublinDublin, Ireland. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Sameeha Sulaiman
Sameeha Sulaiman edited on 27 Dec 2018 2:35 pm
Edits made to:
Infobox (+1/-1 properties)
Article (+2109 characters)
People (+12 cells) (+168 characters)
Further reading (+8 cells) (+599 characters)

Article

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.



Nabriva's leading product in its pipeline is Contepo, an investigational epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including against most contemporary MDR strains. The company gained Contepo through the acquisition of Zavante Therapeutics, its original developer. The FDA has granted Contepo Qualified Infectious Disease Product (QIDP) and Fast Track designations for:

  • Complicated urinary tract infections (cUTI)
  • Complicated intra-abdominal infections (cIAI)
  • Hospital-acquired bacterial pneumonia (HABP) & Ventilator-associated bacterial pneumonia (VABP)
  • Acute bacterial skin and skin structure infections (ABSSSI)

As of November 2018, Nabriva completed the Submission of New Drug Application to the FDA.



Another product in Nabriva's pipeline is Lefamulin, which is a semi-synthetic compound that inhibits the synthesis of bacterial protein. It has completed two Phase 3 trials to evaluate the safety and efficacy of Lefamulin (via IV and oral) in the treatment of adults with community-acquired bacterial pneumonia (CABP). 



The company is also exploring formulations of Lefamulin for pediatric use and for the treatment of other illnesses such as acute bacterial skin and skin structure infection (ABSSSI), sexually transmitted infections (STIs), ventilator-associated bacterial pneumonia (VABP), osteomyelitis, and prosthetic joint infections.

...

Nabriva has also completed a Phase 1 clinical trial for BC-7013, a semi-synthetic compound derived from pleuromutilin, for its potential to be developed as a topical treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs).

People

Name
Role
Related Golden topics

Francesco Maria Lavino

Chief Commercial Officer



Gary Sender

CFO



Jennifer Schranz

Chief Medical Officer



Robert Crotty

General Counsel



Steve Gelone

President & COO



Ted Schroeder

CEO



Further reading

Title
Author
Link
Type

Nabriva snaps up Zavante for its market-ready antibiotic

GlobalData Healthcare

Web

Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections

Nabriva Therapeutics

Web

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:06 am
Edits made to:
Infobox (+2 properties)
Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 8:00 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm

Infobox

Location
Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:51 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:52 pm
Edits made to:
Description (+110/-21 characters)
Topic thumbnail

Nabriva Therapeutics

Biotechnology company

A biopharmaceutical company focused on the research and development of antibiotics to treat serious infections

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:30 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Nabriva Therapeutics

Biotechnology company

Categories

No more activity to show.